Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Egyptian Patients

Trial Profile

Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Egyptian Patients

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DAPA-Egypt
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Feb 2019 Planned initiation date changed from 31 Dec 2018 to 28 Feb 2019.
    • 31 Oct 2018 Planned initiation date changed from 18 Oct 2018 to 31 Dec 2018.
    • 24 Sep 2018 Planned initiation date changed from 31 Aug 2018 to 18 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top